Literature DB >> 7922863

Different pharmacological characteristics of structurally similar benzylisoquinoline analogs, papaverine, higenamine, and GS 389, on isolated rat aorta and heart.

K C Chang1, W S Chong, I J Lee.   

Abstract

In the present study, we compared the pharmacological properties of structurally similar benzylisoquinoline compounds, papaverine, higenamine, and GS 389, using isolated rat aorta and atrial preparations. The three benzylisoquinoline compounds, concentration dependently, relaxed phenylephrine (3 microM) induced contraction of rat aortic rings, with the rank order of potency being higenamine > papaverine > GS 389. They also relaxed high K+ (60 mM) induced contraction, with the rank order of potency being papaverine > GS 389 >> higenamine. The relaxation was not modified by the presence of endothelium. To assess whether these compounds directly interfere with Ca2+ influx, the effects of these compounds on Ca(2+)-induced contraction in Ca(2+)-free media were examined. Among the three compounds, papaverine most strongly inhibited Ca(2+)-induced contraction of both K+ stimulated and phenylephrine-stimulated aorta. Higenamine was least potent in inhibition of Ca(2+)-induced contraction in high K+ depolarized aorta. In atrial tissues, lower concentrations of papaverine increased spontaneous beats and isometric tension, whereas above 30 microM its action was reversed. GS 389 decreased heart rate without affecting the contractility. On the other hand, higenamine concentration dependently increased both heart rate and isometric tension, as well as cyclic AMP levels in atrial tissues as a result of beta-receptor activation. Cyclic AMP and cyclic GMP dependent phosphodiesterases from rat atrial and ventricular tissue homogenates were inhibited by papaverine and GS 389, but not by higenamine. These results suggest that calcium antagonistic action of these compounds is at least in part responsible for vasodilation action, but not for cardiac action.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7922863     DOI: 10.1139/y94-049

Source DB:  PubMed          Journal:  Can J Physiol Pharmacol        ISSN: 0008-4212            Impact factor:   2.273


  6 in total

1.  Upregulation of vascular calcium channels in neonatal piglets with hypoxia-induced pulmonary hypertension.

Authors:  Dinesh K Hirenallur-S; Steven T Haworth; Jeaninne T Leming; James Chang; Guillermo Hernandez; John B Gordon; Nancy J Rusch
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2008-09-05       Impact factor: 5.464

2.  Suppressive effects of processed aconite root on dexamethasone-induced muscle ring finger protein-1 expression and its active ingredients.

Authors:  Taishi Kondo; Tomoaki Ishida; Ke Ye; Marin Muraguchi; Yohei Tanimura; Masato Yoshida; Kan'ichiro Ishiuchi; Tomoki Abe; Takeshi Nikawa; Keisuke Hagihara; Hidetoshi Hayashi; Toshiaki Makino
Journal:  J Nat Med       Date:  2022-02-18       Impact factor: 2.343

3.  Higenamine protects ischemia/reperfusion induced cardiac injury and myocyte apoptosis through activation of β2-AR/PI3K/AKT signaling pathway.

Authors:  Mei-ping Wu; Yi-shuai Zhang; Qian-mei Zhou; Jian Xiong; Yao-rong Dong; Chen Yan
Journal:  Pharmacol Res       Date:  2015-12-30       Impact factor: 7.658

4.  A phase I study on pharmacokinetics and pharmacodynamics of higenamine in healthy Chinese subjects.

Authors:  Sheng Feng; Ji Jiang; Pei Hu; Jian-yan Zhang; Tao Liu; Qian Zhao; Bi-lu Li
Journal:  Acta Pharmacol Sin       Date:  2012-10-22       Impact factor: 6.150

Review 5.  Norcoclaurine synthase: mechanism of an enantioselective pictet-spengler catalyzing enzyme.

Authors:  Alessandra Bonamore; Marco Barba; Bruno Botta; Alberto Boffi; Alberto Macone
Journal:  Molecules       Date:  2010-03-24       Impact factor: 4.411

Review 6.  Pharmacological effects of higenamine based on signalling pathways and mechanism of action.

Authors:  De-Ta Chen; Wu Rao; Xue Shen; Lin Chen; Zi-Jian Wan; Xiao-Ping Sheng; Tian-You Fan
Journal:  Front Pharmacol       Date:  2022-09-15       Impact factor: 5.988

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.